Isquemia
Hematies jóvenes miocárdica
Perfusión
tisular
100
90
80
70
60
50
40
30
20
10
0
Deficit Endogeno EPO Deficit Hierro para
Eritropoyesis Anemia Crónica
Nanas JN et al. J Am Coll Cardiol 2006;48 (12):2486
Nanas JN et al. J Am Coll Cardiol 2006;48 (12):2486
Ponikowsky P et al. Eur Heart Jour 2006
Todos Anemicos No anemicos
70
60
50
40
30
20
10
0
Ferropenia Funcional
Oral o Ev?
¿Fe ev vs Fe oral?
Cobertura: carbohidrato
Hypersensitivity Reactions Type 1
Bailie GR, Clark JA, Lane CE, Lane PL Hypersensitivity reactions and
deaths associated with intravenous iron preparations. Nephrol Dial
Transplant (2005) 20: 1443-1449
Hierro Intravenoso: diferencias
Hierro Intravenoso
Evidencias
Intravenous Iron Alone for the Treatment of Anemia in
Patients With Chronic Heart Failure
Hb g/dL
11.2 ± 0.7 12.6 ± 1.2 0.0007
MLHF
33 ± 19 19 ± 14 0.02
6MWT m
242 ± 78 286 ± 72 0.01
Control Group n= 38
No Anemia Treatment
Intervention Group n= 27
Anemia Correction (Hb12.5-14.5 g/dL)
With rHuEPO β 4000-10000 U sc /1 x week
+ IVI sucrose (Venofer®) NT-proBNP levels at Baseline and Follow Up
Death & CV Hospitalization & Functional Class
ENDPOINTS
Changes of NT-proBNP levels
All cause Death & Hospitalization & the Combined End-Point
Hospital de Dia de la UIC:
“Anemia Clinic”
Hemoglobin (g/dL)
Βaseline 10.9±1.0 10.9±1.0 ns
End of Study 11.3±1.1 ns 13.5±1.5 <0.001 <0.001
Hematocrit (%)
Baseline 33.9±3.1 34.4±2.8 ns
End of Study 34.3±6.6 ns 41.8±4.6 <0.001 <0.001
Ferritin (ng/mL)
Baseline 140.7±123.4 220.7±190.8 ns
End of Study 221.9±270.3 ns 373.9±367.1 ns ns
% TSAT
Baseline 19.9±10.3 23.2±9.9 ns
End of Study 19.6±8.3 ns 31.5±10.5 0.021 0.002
Creatinine (mg/dL)
Baseline 1.4±0.5 1.6±0.5 ns
End of Study 1.5±0.6 ns 1.5±0.4 ns ns
Effect of Treatment of Anemia
7 7
6 6
5 5
Control Group Intervention Group
Baseline End of Study Baseline End of Study
(*baseline & final NT-proNP available in 58 patients)
There were no significant adverse reactions in relation to IV iron
or rHuEPO administration (including uncontrolled hypertension or Thrombosis
40
Nuevas Evidencias?
Hierro Carboximaltosa-Ferinject
Hierro Intravenoso: diferencias 41
500 mg
Ferinject® 15 min
1000 mg
FAIR-HF
• CF II-III NYHA
• Ferritina < 100 µg/L o 100-300 µg/L y TSAT < 20%
• Hb: 9,5-13,5
FAIR-HF
Diseño
Week 24
Stratified
randomization 2:1 Placebo (NaCl i.v.) (n=192)
Nuevas Evidencias?
Hierro Sacarosa
J Card Fail 2007;13(1):14
IRON-HF
Estudio Muticentrico •CF II-IV
•FE<40%
•Hb<12 + TSAT<20 + Ferritina<500
Correction phase*
Week 12
Screening
2 weeks
Peak VO2
Stratified
randomization 1:1:1
Placebo
Conclusiones
uic@hospitaldelmar.cat
www.hospitaldelmar.cat/insuficiencia-cardiaca